When was Life Length founded?

Life Length was founded in 2010 and raised its 1st funding round 5 years after it was founded.

Where is Life Length located?

Life Length is headquartered in Madrid, Spain.

Who is the current CEO of Life Length?

Stephen J Matlin of Life Length. They have also founded 1 company.

How many employees does Life Length have?

As of Jun 30, 2026, the latest employee count at Life Length is 39.

Is Life Length a funded company?

Life Length is a funded company, having raised a total of $2.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 01, 2015.

When was the latest funding round of Life Length?

Life Length's latest funding was a $***** Grant (prize money) round on Jan 11, 2024, with participation from 1 investor.

Where does Life Length rank among its competitors?

Life Length ranks 24th amongst 115 active competitors, of which 38 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Life Length?

Life Length's top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Life Length - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provides telomere length analysis technology for diagnosis. The company offers its proprietary technology for telomerase length detection for the health and aging process. It offers its services to physicians, individuals, researchers, and corporations. The company is involved in the development of biomarkers and its flagship product ONCOCHECK for clinical validation of Telomere Associated Variables (TAVs) as cancer biomarkers by its TAT technology for prostate cancer.

Website: lifelength.com
Social
Email ID: *****@lifelength.com
Phone Number: +1 **********

Key Metrics

Founded Year

2010

Location

Madrid, Spain

Stage

Seed

Total Funding

$2.7M in 6 rounds

Latest Funding Round

Grant (prize money), Jan 11, 2024, $*****

Investors

EIC Fund & 2 more

Ranked

24^th among 115 active competitors

Employee Count

39 as on Jun 30, 2026

Similar Companies

Seer & 142 more

View Life Length's full profile

Life Length has raised a total funding of $2.7M over 6 rounds. Its first funding round was on Sep 01, 2015. Its latest funding round was a Grant (prize money) round on Jan 11, 2024 for $*****. 1 investor participated in its latest round. Life Length has 3 institutional investors.

Here is the list of recent funding rounds of Life Length:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 11, 2024	7457874	Grant (prize money)	7606707	3047856	4819509	7019892
Jul 08, 2019	5035010	Seed	6425420	3767087	4655838	5555559
Dec 31, 2018	6781880	Grant (prize money)	2361338	2529660	2092604	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Life Length's funding rounds and investors

The founders of Life Length is Stephen J Matlin. Stephen J Matlin is the CEO of Life Length.

Here are the details of Life Length's key team members:

Stephen J Matlin: Founder & CEO of Life Length.

View details of Life Length's Founder profiles and Board Members

Life Length's employee count trend

Life Length has 39 employees as of Jun 26. Here is Life Length's employee count trend over the years:

Uncover Life Length's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Life Length include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of Life Length, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Deep Track Capital, City Hill Ventures & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	New Enterprise Associates, Bay City Capital ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
7th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
8th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, Goldstone Investment ... & 12 others	55/100
9th	Segterra (InsideTracker) 2009, Cambridge (United States), Series B	Personalized path for health, wellness, and performance applications	$17.5M	PeakBridge, BASF & 4 others	54/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
24th	Life Length 2010, Madrid (Spain), Seed	Provides telomere length analysis technology for diagnosis	$2.7M	EIC Fund, Europa & 1 others	44/100